Global Depression Therapy And Treatment Market Size is segmented on the basis of antidepressants drugs, devices and therapies. Antidepressants are the largest market segment.
Antidepressants are the most popular treatment methods. Every year more than five billion prescriptions are written globally. Antidepressants segment consists of big pharmaceuticals companies like Eli Lily, Pfizer, GlaxoSmithKline and Forest Laboratories. All these companies are branded drug manufacturers. Some of the popular drugs produced by these companies are Cymbalta (Eli Lily) and Effexor and Pristiq (Pfizer). The devices market is the fastest growing market segment.
1. Pfizer
2. GlaxoSmithKline
3. Forest Laboratories
4. Abbot Laboratories
5. Eli Lilly and Company
6. Merck Sharp &Dohme
7. Sanofi
8. Teva Pharmaceuticals Industries
9. Mayo Clinic
10. Sun Pharmaceuticals
11. Brainsway
12. Fisher Wallace
13. MagVentures
14. Lundbeck
15. BoehringerIngelheim GmbH
16. Roche Holding AG
2. GlaxoSmithKline
3. Forest Laboratories
4. Abbot Laboratories
5. Eli Lilly and Company
6. Merck Sharp &Dohme
7. Sanofi
8. Teva Pharmaceuticals Industries
9. Mayo Clinic
10. Sun Pharmaceuticals
11. Brainsway
12. Fisher Wallace
13. MagVentures
14. Lundbeck
15. BoehringerIngelheim GmbH
16. Roche Holding AG
This AcuteMarketReports covers
1. Historical data
2. Revenue forecasts, growth rates and CAGR upto 2021
3. Industry Analysis
4. Competitive Analysis
5. Key geographic growth data
6. Deep profiles top competitive companies
1. Historical data
2. Revenue forecasts, growth rates and CAGR upto 2021
3. Industry Analysis
4. Competitive Analysis
5. Key geographic growth data
6. Deep profiles top competitive companies
For More Information visit: http://www.acutemarketreports.com/report/global-depression-therapy-treatment-market
Table of Content
Chap 1. Executive Summary
1.1. Depression therapy, device and drugs market
1.2. Methodology For Market Estimation
1.1. Depression therapy, device and drugs market
1.2. Methodology For Market Estimation
Chap 2. Market Overview –Depression Is A Major Concern Worldwide
2.1. Introduction
2.2. Depression is most common in 40-60 years of age group
2.3. Types of Depressions
2.3.1. Seasonal Affective Disorder (SAD)
2.3.2. Uni-polar or Major Depression
2.3.3. Dysthymia or Dysthymia Disorder
2.3.4. Postpartum Depression
2.3.5. Atypical Depression
2.3.5.1. Psychotic Depression
2.3.5.2. Bipolar Disorder
2.4. Value Chain Analysis
2.4.1. For Drugs
2.4.1.1. Manufacturers
2.4.1.2. Distributors
2.4.1.3. Retailers
2.4.1.4. End-Users
2.4.2. For Devices
2.4.2.1. Manufacturers
2.4.2.2. Distributors
2.4.2.3. End-Users
2.5. Drivers
2.5.1. Growing acceptance of Depression in the developing nations
2.5.2. Increase in sales of antidepressants due to unhealthy life styles
2.6. Restraints
2.6.1. High price of Psycho therapy is a major restraint
2.6.2. Patents expiry is a major issue
2.6.3. Regulatory Compliance is important for the market to grow
2.7. Challenges
2.7.1. Generic Vs Branded – leads to price reduction
2.8. Opportunities
2.8.1. Significant Unmet Clinical needs has tremendous market potential
2.8.2. Decline in drug market offset bygrowing demand for personal therapies & devices
2.9. Key Findings
2.9.1. Negative Growth Rate in Antidepressants market
2.9.2. Rising acceptance for depression treatment in Asia Pacific
2.9.3. Market is shifting from branded to generic drugs
2.10. Strategic Recommendations
2.10.1. Market needs new anti depressant drugs
2.1. Introduction
2.2. Depression is most common in 40-60 years of age group
2.3. Types of Depressions
2.3.1. Seasonal Affective Disorder (SAD)
2.3.2. Uni-polar or Major Depression
2.3.3. Dysthymia or Dysthymia Disorder
2.3.4. Postpartum Depression
2.3.5. Atypical Depression
2.3.5.1. Psychotic Depression
2.3.5.2. Bipolar Disorder
2.4. Value Chain Analysis
2.4.1. For Drugs
2.4.1.1. Manufacturers
2.4.1.2. Distributors
2.4.1.3. Retailers
2.4.1.4. End-Users
2.4.2. For Devices
2.4.2.1. Manufacturers
2.4.2.2. Distributors
2.4.2.3. End-Users
2.5. Drivers
2.5.1. Growing acceptance of Depression in the developing nations
2.5.2. Increase in sales of antidepressants due to unhealthy life styles
2.6. Restraints
2.6.1. High price of Psycho therapy is a major restraint
2.6.2. Patents expiry is a major issue
2.6.3. Regulatory Compliance is important for the market to grow
2.7. Challenges
2.7.1. Generic Vs Branded – leads to price reduction
2.8. Opportunities
2.8.1. Significant Unmet Clinical needs has tremendous market potential
2.8.2. Decline in drug market offset bygrowing demand for personal therapies & devices
2.9. Key Findings
2.9.1. Negative Growth Rate in Antidepressants market
2.9.2. Rising acceptance for depression treatment in Asia Pacific
2.9.3. Market is shifting from branded to generic drugs
2.10. Strategic Recommendations
2.10.1. Market needs new anti depressant drugs
Click Here To Download Detail Report: http://www.acutemarketreports.com/request-free-sample/48532
Chap 3. Market Segmentation
3.1. Antidepressants
3.2. Consumption of Antidepressants
3.2.1. Generic Drugs are preferred OVER Branded Antidepressants due to lower cost
3.3. Selective serotonin reuptake inhibitors (SSRIs)
3.3.1. Prozac (Fluoxetine)
3.3.2. Paroxetine (Paxil)
3.3.3. SERTRALINE (Zoloft)
3.3.4. Escitalopram oxalate (Lexapro)
3.3.5. Citalopram (Celexa)
3.3.6. Serotonin and norepinephrine reuptake inhibitors (SNRIs).
3.3.7. Duloxetine (Cymbalta)
3.3.8. Effexor
3.3.9. Norepinephrine and dopamine reuptake inhibitors (NDRIs)
3.4. Atypical antidepressants
3.4.1. Trazodone
3.4.2. Tricyclic antidepressants (TCA)
3.4.3. Tofranil (Imipramine)
3.4.4. Monoamine oxidase inhibitors (MAOIs)
3.4.4.1. Tranylcypromine (Parnate)
3.4.5. Phenelzine (Nardil)
3.4.6. Other medications
3.5. Therapies
3.1. Antidepressants
3.2. Consumption of Antidepressants
3.2.1. Generic Drugs are preferred OVER Branded Antidepressants due to lower cost
3.3. Selective serotonin reuptake inhibitors (SSRIs)
3.3.1. Prozac (Fluoxetine)
3.3.2. Paroxetine (Paxil)
3.3.3. SERTRALINE (Zoloft)
3.3.4. Escitalopram oxalate (Lexapro)
3.3.5. Citalopram (Celexa)
3.3.6. Serotonin and norepinephrine reuptake inhibitors (SNRIs).
3.3.7. Duloxetine (Cymbalta)
3.3.8. Effexor
3.3.9. Norepinephrine and dopamine reuptake inhibitors (NDRIs)
3.4. Atypical antidepressants
3.4.1. Trazodone
3.4.2. Tricyclic antidepressants (TCA)
3.4.3. Tofranil (Imipramine)
3.4.4. Monoamine oxidase inhibitors (MAOIs)
3.4.4.1. Tranylcypromine (Parnate)
3.4.5. Phenelzine (Nardil)
3.4.6. Other medications
3.5. Therapies
Latest Report:
Global Continuous Glucose Monitoring System Market: http://bit.ly/1SVutJD
About Us:
Acute Market Reports is the most sufficient collection of market intelligence services online. It is your only source that can fulfill all your market research requirements. We provide online reports from over 100 best publishers and upgrade our collection regularly to offer you direct online access to the world’s most comprehensive and recent database with expert perceptions on worldwide industries, products, establishments and trends. Our database consists of 200,000+ market research reports with detailed & minute market research.
Our market research professionals have detailed knowledge of the publishers and different kinds of reports in their particular business domains. They will guide you in finding the complete range of available market research reports, review the scope and procedure of the research studies that you select, and provide you guidance in order to assist you in taking the correct business decisions related to the purchase of the market research reports.
Acute Market Reports
Mr. Chris Paul
Office No 101, 1st Floor,
Aditi Mall, Baner,
Pune, MH, 411045
India
Toll Free(US/CANADA): +1-855-455-8662
Email: sales@acutemarketreports.com
Blog: http://mrramr.blogspot.in/
Website: Acute Market Reports
Mr. Chris Paul
Office No 101, 1st Floor,
Aditi Mall, Baner,
Pune, MH, 411045
India
Toll Free(US/CANADA): +1-855-455-8662
Email: sales@acutemarketreports.com
Blog: http://mrramr.blogspot.in/
Website: Acute Market Reports
No comments:
Post a Comment